India’s COVID19 Vaccine Launch
BBIL-ICMR COVID-19 Vaccine Launch Expected By August 2020
In order to step up efforts for a possible vaccine for the novel coronavirus, the Indian Council of Medical Research (ICMR) and Bharat Biotech International Limited (BBIL) have come together to take the necessary steps.
The COVID-19 vaccine Covaxin by Bharat Biotech and ICMR could now be launched by August for the public use. The ICMR partnered with BBIL and developed the BBV152 COVID vaccine, the indigenous Covid-19 vaccine.
India’s first indigenous Covid-19 vaccine’s clinical trials will be conducted in 12 institutes selected by the ICMR. After completion of all clinical trials, ICMR is expected to launch the vaccine latest by August 15, 2020, for public health use.
After the completion of clinical trials, ICMR expects to launch the Covid vaccine by August 15 and has written to all stockholders to treat it as a top priority and fast track clinical trials of the vaccine.
The ICMR told the selected institutes that the final outcome will depend on the cooperation of all clinical trial sites involved in this project and that BBIL is working expeditiously to meet the target.
In collaboration with the National Institute of Virology (NIV) and ICMR, the Hyderabad-based Bharat Biotech developed the COVID-19 vaccine, Covaxin successfully. The SARS-CoV-2 strain was transferred to Bharat Biotech after being isolated in NIV, Pune.
In the BSL-3 (Bio-Safety Level 3) High Containment facility of Bharat Biotech at the Genome Valley, Hyderabad, this indigenous inactivated vaccine was developed and manufactured.
After the company had submitted results generated from preclinical studies, demonstrating safety and immune response, the Ministry of Health & Family Welfare and the Drug Controller General of India- Central Drugs Standard Control Organisation had granted permission to initiate Phase I & II Human clinical trials.
India’s COVID19 Vaccine Launch, India’s COVID19 Vaccine Launch Expected By August 15, 2020.